Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.91 |
| ▸ | AKT2 | P31751 | 15/20 | 0.91 |
| ▸ | AKT3 | Q9Y243 | 15/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.91 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30815384 | 1.00 | AKT1 (0.91) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL30574963 | 0.95 | AKT1 (1.00) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL2176743 | 0.95 | AKT1 (1.00) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL27227203 | 0.94 | AKT1 (0.88) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL30815569 | 0.94 | AKT1 (0.88) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL2190097 | 0.92 | AKT1 (0.94) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL30802341 | 0.92 | AKT1 (0.88) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL2174059 | 0.91 | AKT1 (0.87) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL2174671 | 0.91 | AKT1 (1.00) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL2174099 | 0.90 | AKT1 (0.82) | AKT1AKT2AKT3CYP2C9CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | AKT1 2/4885AKT2 3/4885AKT3 4/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | AKT1 2/4885AKT2 3/4885AKT3 4/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | AKT1 2/4885AKT2 3/4885AKT3 4/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | AKT1 2/4885AKT2 3/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.